News | October 25, 2021
Syngene reports better than expected revenues, margin pressure in Q1FY22: ICICI Direct
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
India reports 18 lakh stroke cases a year with 25 per cent patients below the age of 50
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
The authority also allowed mix and match of booster doses once the primary vaccine has been administered.
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
The panel concurred that these supplements resolved post-Covid-19 fatigue and muscle weakness
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
Subscribe To Our Newsletter & Stay Updated
